Pearl, founded in 2019, develops artificial intelligence for dentistry. Its core technology is computer vision applied to dental radiographs: models that analyse X-ray images and identify pathologies, restorations and anatomical structures in real time. The company's platform is FDA-cleared diagnostic software, and Pearl holds multiple FDA clearances spanning both 2D and 3D imaging - reportedly the first and only company to hold both.
The work sits at the intersection of medical imaging and regulated AI. Technical domains include computer vision, real-time image analysis and 2D and 3D dental imaging analysis, with the corresponding constraints of building diagnostic tools that must clear regulatory review. The platform is designed to support more precise diagnoses, patient communication and practice efficiency, helping clinicians to see more clearly and diagnose more confidently.
Pearl's platform is used by dental practices in more than 120 countries and integrates with over 40 practice management and imaging systems. It serves thousands of practices, as well as dental support organisations and dental education institutions. The company describes its mission as elevating patient care through AI and establishing a higher standard of care in dentistry.
